治疗肥胖的肠促胰岛素:更像是尼古丁贴片,而不是灵丹妙药。

IF 2.7 3区 医学 Q3 PHARMACOLOGY & PHARMACY
Expert Opinion on Pharmacotherapy Pub Date : 2025-09-01 Epub Date: 2025-09-10 DOI:10.1080/14656566.2025.2557458
Isabella Dippel, Megan Adelman, Kevin M Olson, Alexis Holt, Jahmae Collins, Andrea Reddest, Nicholas W Carris
{"title":"治疗肥胖的肠促胰岛素:更像是尼古丁贴片,而不是灵丹妙药。","authors":"Isabella Dippel, Megan Adelman, Kevin M Olson, Alexis Holt, Jahmae Collins, Andrea Reddest, Nicholas W Carris","doi":"10.1080/14656566.2025.2557458","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Obesity is a pandemic and a key driver of type 2 diabetes mellitus, heart disease, and healthcare spending. Incretin drug therapy prescribing for obesity has dramatically increased in recent years, necessitating researchers and clinicians to rapidly update their understanding of and approach to obesity management.</p><p><strong>Areas covered: </strong>We assembled a multi-disciplinary team of experts to identify and complete a narrative review of the relevant literature regarding behavioral interventions, nutrition, physical activity, incretin drug therapy for weight loss, and the management of incretin drug adverse effects.</p><p><strong>Expert opinion: </strong>Incretin drug therapy can produce significant weight loss in properly selected individuals. However, many do not continue therapy indefinitely. To maximize the benefits of incretin therapy, individuals should receive behavioral support to increase their physical activity, the healthfulness of their diet, protein intake, awareness of food triggers, and ultimately their probability of short-term weight loss and long-term weight maintenance regardless of the long-term use of incretin therapy.</p>","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1359-1371"},"PeriodicalIF":2.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Incretins for obesity: closer to a nicotine patch than a silver bullet.\",\"authors\":\"Isabella Dippel, Megan Adelman, Kevin M Olson, Alexis Holt, Jahmae Collins, Andrea Reddest, Nicholas W Carris\",\"doi\":\"10.1080/14656566.2025.2557458\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Obesity is a pandemic and a key driver of type 2 diabetes mellitus, heart disease, and healthcare spending. Incretin drug therapy prescribing for obesity has dramatically increased in recent years, necessitating researchers and clinicians to rapidly update their understanding of and approach to obesity management.</p><p><strong>Areas covered: </strong>We assembled a multi-disciplinary team of experts to identify and complete a narrative review of the relevant literature regarding behavioral interventions, nutrition, physical activity, incretin drug therapy for weight loss, and the management of incretin drug adverse effects.</p><p><strong>Expert opinion: </strong>Incretin drug therapy can produce significant weight loss in properly selected individuals. However, many do not continue therapy indefinitely. To maximize the benefits of incretin therapy, individuals should receive behavioral support to increase their physical activity, the healthfulness of their diet, protein intake, awareness of food triggers, and ultimately their probability of short-term weight loss and long-term weight maintenance regardless of the long-term use of incretin therapy.</p>\",\"PeriodicalId\":12184,\"journal\":{\"name\":\"Expert Opinion on Pharmacotherapy\",\"volume\":\" \",\"pages\":\"1359-1371\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Pharmacotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14656566.2025.2557458\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14656566.2025.2557458","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

肥胖症是一种流行病,是2型糖尿病、心脏病和医疗保健支出的主要驱动因素。近年来,肠促胰岛素药物治疗肥胖处方急剧增加,需要研究人员和临床医生迅速更新他们对肥胖管理的理解和方法。涉及领域:我们组建了一个多学科的专家团队,以确定并完成有关行为干预、营养、体育活动、肠促胰岛素药物治疗减肥和肠促胰岛素药物不良反应管理的相关文献的叙述性综述。专家意见:肠促胰岛素药物治疗在适当选择的个体中可以产生显著的体重减轻。然而,许多人并没有无限期地继续治疗。为了最大限度地发挥肠促胰岛素治疗的益处,个体应该接受行为支持,以增加他们的身体活动,健康的饮食,蛋白质摄入量,对食物触发因素的认识,最终,无论长期使用肠促胰岛素治疗,他们短期体重减轻和长期体重维持的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Incretins for obesity: closer to a nicotine patch than a silver bullet.

Introduction: Obesity is a pandemic and a key driver of type 2 diabetes mellitus, heart disease, and healthcare spending. Incretin drug therapy prescribing for obesity has dramatically increased in recent years, necessitating researchers and clinicians to rapidly update their understanding of and approach to obesity management.

Areas covered: We assembled a multi-disciplinary team of experts to identify and complete a narrative review of the relevant literature regarding behavioral interventions, nutrition, physical activity, incretin drug therapy for weight loss, and the management of incretin drug adverse effects.

Expert opinion: Incretin drug therapy can produce significant weight loss in properly selected individuals. However, many do not continue therapy indefinitely. To maximize the benefits of incretin therapy, individuals should receive behavioral support to increase their physical activity, the healthfulness of their diet, protein intake, awareness of food triggers, and ultimately their probability of short-term weight loss and long-term weight maintenance regardless of the long-term use of incretin therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.60
自引率
3.10%
发文量
163
审稿时长
4-8 weeks
期刊介绍: Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信